Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial

<p><strong>Background:</strong> Vancomycin is the most widely used antibiotic for neonatal Gram-positive sepsis, but clinical outcome data of dosing strategies are scarce. The NeoVanc programme comprised extensive preclinical studies to inform a randomised controlled trial to asses...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän:	Hill, L, Clements, MN, Turner, MA, Dona, D, Lutsar, I, Jacqz-Aigrain, E, Heath, P, Roilides, E, Rawcliffe, L, Alonso-Diaz, C, Baraldi, E, Dotta, A, Ilmoja, M-L, Mahaveer, A, Metsvaht, T, Mitsiakos, G, Papevangelou, V, Sarafidis, K, Walker, AS, Sharland, M
Materialtyp:	Journal article
Språk:	English
Publicerad:	Elsevier 2021

Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial

Liknande verk